INTRODUCTION {#S1}
============

Zeta-associated protein-70 (*ZAP70*), a member of the Syk family of tyrosine kinases, plays an important role in T-cell receptor signaling, natural killer cell activation, and early B-cell development.([@R1]) *ZAP70* protein is not expressed in most normal mature B-cells, but is expressed in various B- and T-cell lymphomas.([@R2]--[@R4]) In previous studies, *ZAP70* protein expression measured by flow cytometry was associated with unmutated immunoglobulin heavy chain variable region (IGHV) genes and poorer clinical outcome in patients with chronic lymphocytic leukemia.([@R5]--[@R11]) Subsequent attempts to implement *ZAP70* analysis in clinical flow cytometry laboratories, however, have been have been fraught with difficulty; this approach is technically challenging and results often have been unreliable.

Detection of *ZAP70* protein by immunohistochemistry using tissue sections of chronic lymphocytic leukemia is an easy and inexpensive technique. Potential criticisms of this approach, however, are that immunohistochemistry is not quantitative and that interpretation is somewhat subjective. To address these issues, we compared immunohistochemistry for *ZAP70* protein with the presence of *ZAP70* messenger RNA (mRNA) transcripts measured by a semi-quantitative reverse-transcriptase polymerase chain reaction (QRT-PCR) assay. We show that detection of *ZAP70* protein assessed by immunohistochemistry strongly correlates with *ZAP70* mRNA expression assessed by QRT-PCR assay, and that the results of both methods correlate with the somatic mutation status of the IGHV genes in chronic lymphocytic leukemia. Further, our results show that *ZAP70* protein assessed by immunohistochemistry predicts time to progression.

MATERIALS AND METHODS {#S2}
=====================

Patient Characteristics {#S3}
-----------------------

The Institutional Review Board at The University of Texas M.D. Anderson Cancer Center approved this study. Informed consent was provided according to the Declaration of Helsinki. Sixty-three patients with chronic lymphocytic leukemia, according to the criteria of the World Health Organization Classification system ([@R12]), were included in this study. The clinical characteristics of these patients are summarized in [Table 1](#T1){ref-type="table"}. We selected patients based on the availability of clinical material and the completeness of long-term follow-up. All patients were previously untreated at the time of IGHV sequence analysis and *ZAP70* testing. The median age of patients was 58 years (range 27 to 76 years) and 70% were male (44 men and 19 women). The majority were in modified intermediate-risk stage (Rai 1/2, 79%), with low- and high-risk stages constituting 10% and 11% of patients, respectively. For the analysis of time to progression, we defined the start date as the date the bone marrow sample, which was tested for *ZAP70* expression, was obtained from the patient for evaluation of chronic lymphocytic leukemia at our institution. At the time of testing, patients were a median of 26 months (range 1--129 months) from initial diagnosis by history.

Forty-one patients (65%) had symptomatic and/or advanced disease meeting National Cancer Institute (NCI) sponsored guidelines for treatment,([@R13]) and received therapy within six weeks of IGHV sequence analysis and *ZAP70* testing. The remaining 22 patients were evaluable for disease progression: four patients received rituximab as a phase II study of early intervention ([@R14]) without meeting NCI criteria for therapy, and were censored at the time of rituximab administration; seven received fludarabine, cyclophosphamide and rituximab (FCR) with (n=1) or without (n=6) alemtuzumab; five received rituximab with (n=1) or without (n=4) alemtuzumab; and six remained without requirement for therapy at 21 to 77 months of follow-up. Ten patients died during follow-up, and median survivor follow-up was 42 months (range 29--84 months).

Assessment of *ZAP70* protein expression by immunohistochemistry and flow cytometry {#S4}
-----------------------------------------------------------------------------------

Immunohistochemical staining for *ZAP70* protein was performed in all 63 patients using routinely fixed and processed paraffin-embedded tissue sections of bone marrow core biopsies and/or clot sections and a specific monoclonal antibody (Upstate Cell Signaling Systems, Lake Placid, NY, USA), as described previously.([@R2]) All cases were scored independently by two hematopathologists (R.K. and J.A.) without knowledge of the IGHV somatic mutation status. Cases were scored as 0 (negative), 1+ (weakly positive; granular cytoplasmic staining with nuclear blush in the majority of tumor cells), or 2+ (strongly positive in the majority of tumor cells, approximating the expression of normal T-cells) ([Figure 1](#F1){ref-type="fig"}). For statistical analysis, cases with 1+ and 2+ expression were combined and designated as positive. For all cases there was agreement with respect to positivity or negativity. The flow cytometry assay for *ZAP70* protein expression was performed by the Chronic Lymphocytic Leukemia Research Consortium laboratory, as described previously.([@R15])

Isolation of total RNA and evaluation of IGHVgenes {#S5}
--------------------------------------------------

Total RNA was extracted from purified chronic lymphocytic leukemia cells isolated from peripheral blood.([@R6]) All preparations contained ≥97% cells positive for CD5 and CD19. The IGHV somatic mutation status was determined as described previously.([@R6]) Cases were designated as unmutated if there were fewer than 2% mutations (≥ 98% homology to germline sequences), or as mutated if there were 2% or more mutations (\<98% homology to germline sequences) compared to the germ-line sequences.([@R16])

Semi-Quantitative Reverse Transcriptase-Polymerase Chain Reaction Assay {#S6}
-----------------------------------------------------------------------

*ZAP70* mRNA transcripts were assessed by a QRT-PCR assay using TaqMan® technology and a PRISM 7000 Sequence Detector (Applied Biosystems, Foster City, California) in 60 patients for whom sufficient total RNA was available. Each PCR reaction (25 μL) contained 50 ng cDNA, 1X TaqMan® Universal PCR Master Mix without AmpErase® UNG, unlabeled PCR primers, specific *ZAP70* primers, and a 6-carboxy fluorescein (FAM™)-labeled TaqMan® MGB probe. The *ZAP70* primers were designed from sequences in exons 2 and 3 (Assays-on-Demand Gene Expression system, Applied Biosystems). Amplification of 18S ribosomal RNA (rRNA) was performed in all cases to normalize *ZAP70* values. The 18S rRNA probe is labeled with VIC™ (Pre-Developed TaqMan® Assay Reagents, Applied Biosystems). After incubation at 95°C (10 minutes), the cDNA was amplified for 40 cycles of denaturation (95°C for 15 seconds) and combined annealing/extension (60°C for 1 minute). Each sample was analyzed in duplicate. Expression was categorized as positive (≤ 25 cycles) or negative (\>25 cycles). We determined the cycle number cut-points based on the Martingale residuals from a null Cox proportional hazards model predicting time-to-treatment in a series of 92 patients; 25 cycles marks the cut-point for *ZAP70* mRNA expression.

RESULTS {#S7}
=======

Immunohistochemical staining for *ZAP70* protein in a total of 63 cases demonstrated that 27 cases were negative for *ZAP70* expression and 36 were positive ([Figure 1](#F1){ref-type="fig"}). There was a strong correlation between *ZAP70* expression assessed by immunohistochemistry and QRT-PCR assay in the 60 chronic lymphocytic leukemia cases for which sufficient total RNA was available to perform the QRT-PCR assay (p=8.2x10^−12^, Fisher's Exact Test) ([Table 2a](#T2){ref-type="table"}). All cases that were positive by immunohistochemistry were also positive by QRT-PCR assay (34 of 34 cases); 21 of 26 (81%) cases negative by immunohistochemistry were also negative by QRT-PCR assay. The discordant cases (5 of 26, 19%) were positive by QRT-PCR assay, but negative by immunohistochemistry.

Of the 63 cases, 30 cases had mutated and 33 had unmutated IGHV genes. The somatic mutation status correlated significantly with *ZAP70* expression assessed by QRT-PCR assay and immunohistochemistry (p=0.00076 and p=0.000071, respectively, Fisher's Exact Test) ([Tables 2b](#T3){ref-type="table"} and [2c](#T4){ref-type="table"}). Most unmutated cases were positive for *ZAP70* by QRT-PCR assay (29 of 34 cases, 85%) ([Table 2b](#T3){ref-type="table"}) and immunohistochemistry (29 of 35 cases, 83%) ([Table 2c](#T4){ref-type="table"}). Most mutated cases were negative for *ZAP70* by QRT-PCR assay (15 of 26 cases, 58%)([Table 2b](#T3){ref-type="table"}) and immunohistochemistry (19 of 28 cases, 68%)([Table 2c](#T4){ref-type="table"}). Of the 9 mutated cases that expressed *ZAP70* by immunohistochemistry, 2 belonged to the VH family 3--21.

Nineteen cases showed discordance between IGHV somatic mutation status and *ZAP70* expression assessed by immunohistochemistry and/or QRT-PCR assay. Of the 13 discordant cases with mutated IGHV genes, eight were positive for *ZAP70* expression by both immunohistochemistry and QRT-PCR assay, and one was positive by immunohistochemistry, but unevaluable by QRT-PCR assay. The remaining four cases were positive by QRT-PCR assay, but negative by immunohistochemistry. Of the six discordant cases with unmutated IGHV genes, five were negative for *ZAP70* expression by both immunohistochemistry and QRT-PCR assay. The remaining case was positive by QRT-PCR assay, but negative by immunohistochemistry.

Correlation with Clinical Outcome {#S8}
---------------------------------

Twenty-two patients not requiring immediate therapy (≤ 6 weeks) were evaluable for disease progression. *ZAP70* positivity by immunohistochemistry was associated with increased risk of progression to therapy requirement (3 year risk 83% vs. 31% for *ZAP70* negative by immunohistochemistry, p=0.03, [Figure 2a](#F2){ref-type="fig"}). *ZAP70* positivity by QRT-PCR assay and flow cytometry showed a similar trend, with lesser degrees of statistical significance (p=0.15 and 0.08 for QRT-PCR assay and flow cytometry, respectively) (data not shown). In contrast, the association between unmutated IGHV status and progression to therapy was weak (p=0.27, [Figure 2b](#F2){ref-type="fig"}). Notably, two of the four patients with mutated IGHV patients who progressed to therapy requirement showed discordant *ZAP70* positivity by immunohistochemistry.

The rate of complete remission for the 41 patients who received FCR therapy was not significantly different between *ZAP70* positive and negative patients (p=0.45, 0.70 and 1.0 for immunohistochemistry, QRT-PCR assay, and flow cytometry, respectively), nor was it different between patients with unmutated and mutated IGHV genes (p=0.28). Neither *ZAP70* expression nor IGHV mutation status affected survival within the current duration of follow-up (p\>0.35 for all comparisons).

DISCUSSION {#S9}
==========

The initial studies of the association between *ZAP70* protein expression by flow cytometry and IGHV somatic mutation status demonstrated a high degree of concordance. In the study by Crespo and co-workers,([@R9]) all 21 mutated cases were negative for *ZAP70*, and the vast majority of unmutated cases (32 of 35, 91%) were positive for *ZAP70*. A few unmutated cases (3 of 35, 9%) were negative for *ZAP70* by flow cytometry, but weakly expressed *ZAP70* protein evaluated by Western blot assay. In a larger study of 167 patients by Orchard and co-workers,([@R8]) a small subset of mutated cases expressed *ZAP70* protein (5%), and a small subset of unmutated cases (13%) were negative. Since then, other studies have demonstrated a higher degree of discordance between *ZAP70* protein expression and IGHV somatic mutation status. In these studies the percentage of unmutated cases that fail to express *ZAP70*, by either flow cytometry or immunohistochemistry, has ranged from 6% to 29%, and the percentage of mutated cases that express *ZAP70* has ranged from 5% to 32%.([@R2], [@R3], [@R9], [@R10], [@R15], [@R17]--[@R19]) The degree of discordance between *ZAP70* expression and IGHV mutation status observed in our study is consistent with these findings. By immunohistochemistry we found that 20% of unmutated cases failed to express *ZAP70* and 29% of mutated cases expressed *ZAP70*. Two of the mutated cases that expressed *ZAP70* by immunohistochemistry belonged to the VH3-21 family, which has been associated with a poor prognosis and expression of *ZAP70*.([@R18]) By QRT-PCR assay we found that 15% of unmutated cases failed to express *ZAP70* mRNA transcripts and 38% of mutated cases expressed *ZAP70* mRNA transcripts. We found that no cases that were positive for *ZAP70* by immunohistochemistry, but negative by QRT-PCR assay. However, there were a small subset of cases that were negative by immunohistochemistry, but positive by QRT-PCR assay, presumably due to the greater sensitivity of the QRT-PCR assay compared with immunohistochemistry.

Because the stability of *ZAP70* expression and IGHV mutation status in cases that have undergone clonal evolution over the disease course and therapeutic interventions is unclear, we chose to focus our study on previously untreated patients. Consistent with data presented by other investigators using flow-cytometry based assays of *ZAP70* protein expression,([@R9], [@R15]) our study shows that patients with *ZAP70*-positive chronic lymphocytic leukemia have more aggressive disease with earlier time to therapy requirement. Although immunohistochemistry was the only method associated with a significant p-value, all three methods showed the same trend. The results of the QRT-PCR and flow cytometry assays may have been affected by the smaller number of samples available for analysis (n=60 and 48, respectively).

Initial research studies demonstrated that *ZAP70* protein expression by flow cytometry is a reliable surrogate marker of IGHV gene mutation status. However, introduction of this assay into the diagnostic flow cytometry laboratory as a clinical test has been problematic.([@R19]) *ZAP70* protein is a labile, intracellular antigen that is weakly expressed by chronic lymphocytic leukemia cells. Furthermore, assessment of *ZAP70* protein using commercially available antibodies obtained from different vendors has correlated poorly with IGHV gene mutation status. To address this problem, Bakke and co-workers([@R20]) proposed a ratio metric method to normalize this effect. Others have recommended using a secondary antibody.([@R8]) An inherent advantage of immunohistochemistry is its applicability to paraffin-embedded specimens, eliminating the need for stored fresh specimens. It is particularly useful in retrospective analyses of clinical trials that were completed before assays for *ZAP70* became available. Within our relatively small patient cohort, the performance of *ZAP70* immunohistochemistry was at least equal to that of QRT-PCR and flow cytometry assays in its correlation with IGHV mutation status and its association with disease progression.
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![Immunohistochemistry for *ZAP70* in chronic lymphocytic leukemia involving bone marrow\
(A) A representative case showing an interstitial infiltrate of small, mature-appearing lymphoid cells (hematoxylin and eosin, 200X). (B) In this case the chronic lymphocytic leukemia cells are negative for *ZAP70*, but interspersed benign T-cells are strongly positive. (C) In this case the chronic lymphocytic leukemia cells show weak (1+) *ZAP70* staining. (D) In this case the chronic lymphocytic leukemia cells show strong (2+) *ZAP70* staining. (B-D, immunohistochemistry with hematoxylin counterstain, 200X).](nihms217756f1){#F1}

###### Progression to first therapy

\(A\) *ZAP70* positivity by immunohistochemistry was associated with increased risk of progression to therapy requirement (n=22; 3 year risk 83% vs. 31% for *ZAP70* negative by immunohistochemistry, p=0.03). (B). In contrast to *ZAP70* positivity by immunohistochemistry, the association between unmutated IGHV status and progression to therapy was weak (n=22; p=0.27).
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###### 

Clinical Characteristics

  Characteristic                          Median (Range)
  --------------------------------------- ---------------------
  Age (years)                             58 (27 -- 76)
  Male Gender                             44 (70%)
  Date of Test                            08/00 -- 11/04
  Diagnosis to Test (months)              26 (1 -- 129)
                                          
  Rai stage 0                             6 (10%)
  Rai stage 1--2                          50 (79%)
  Rai stage 3--4                          7 (11%)
                                          
  Hemoglobin (g/dL)                       13.0 (9.9 -- 17.0)
  White Cell Count (x109/L)               35.7 (7.5 -- 255.0)
  Platelets (x109/L)                      177 (39 -- 351)
  B2-microglobulin (mg/L)                 3.0 (1.3 -- 7.4)
                                          
  Unmutated IGHV                          33/63 (52%)
  *ZAP70* Immunohistochemistry Positive   36/63 (57%)
  *ZAP70* QRT-PCR Assay Positive          39/60 (65%)
  *ZAP70* Flow Cytometry Positive         24/48 (50%)

###### 

*ZAP70* Expression Assessed by Immunohistochemistry and QRT-PCR assay

  Immunohistochemistry   QRT-PCR−      QRT-PCR+
  ---------------------- ------------- --------------
  Negative               21/26 (81%)   5/26 (19%)
  Positive               0/34 (0%)     34/34 (100%)

p=8.238 x 10^−12^

###### 

IGHV mutation status and *ZAP70* Expression Assessed by QRT-PCR assay

  IGHV        QRT-PCR−      QRT-PCR+
  ----------- ------------- -------------
  Mutated     15/26 (62%)   11/26 (38%)
  Unmutated   5/34 (15%)    29/34 (85%)

p=0.00076

###### 

IGHV mutation status and *ZAP70* Expression Assessed by Immunohistochemistry

  IGHV        Immunohistochemistry −   Immunohistochemistry +
  ----------- ------------------------ ------------------------
  Mutated     19/28 (71%)              9/28 (29%)
  Unmutated   6/35 (20%)               29/35 (80%)

p=0.000071
